Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis

The metabolomics approach represents the last downstream phenotype and is widely used in clinical studies and drug discovery. In this paper, we outline recent advances in the metabolomics research of autoimmune diseases (ADs) such as rheumatoid arthritis (RA), multiple sclerosis (MuS), and systemic lupus erythematosus (SLE). The newly discovered biomarkers and the metabolic mechanism studies for these ADs are described here. In addition, studies elucidating the metabolic mechanisms underlying these ADs are presented. Metabolomics has the potential to contribute to pharmacotherapy personalization; thus, we summarize the biomarker studies performed to predict the personalization of medicine and drug response.

Automated summary

This paper outlines recent advances in metabolomics research of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, describing newly discovered biomarkers and metabolic mechanism studies for these diseases. It also presents studies elucidating the metabolic mechanisms underlying these diseases and summarizes biomarker studies aimed at predicting personalized medicine and drug response.